The authors reply

New England Journal of Medicine

Volumn 370, Issue 5, 2014, Pages 479-480

  Von Hoff, Daniel D ^a   Goldstein, David ^b   Renschler, Markus F ^c  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; OSTEONECTIN; PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; CANCER LOCALIZATION; CANCER SURVIVAL; DISEASE SEVERITY; DRUG COST; FATIGUE; HUMAN; LETTER; NEUROPATHY; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; ADENOCARCINOMA; FEMALE; MALE; NOTE; PANCREAS TUMOR;

ADENOCARCINOMA; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; PACLITAXEL; PANCREATIC NEOPLASMS;

EID: 84893029048     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1314761     Document Type: Letter

References (2)

1. FDA approved drugs. 2013 (http://www.centerwatch.com/drug-information/ fda-approved-drugs).
2. Goldstein D, Von Hoff DD, Moore M, et al. Evaluation of peripheral neuropathy in a phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) vs gem alone for patients with metastatic adenocarcinoma of the pancreas. Presented at ECCO17-ESMO38-ESTRO32-ESSO33, Amsterdam, September 27-October 1, 2013:2.583. abstract.